Eisai and Biogen's Alzheimer's drug Leqembi continued to slow progress of the disease with no new safety issues four years ...

Long-term data presented at the Alzheimer’s Association International Conference show Leqembi can help patients stay in the ...

Rumors of Biogen’s disagreements with Eisai have been greatly exaggerated, CEO Chris Viehbacher said during a second quarter ...

Japan’s Eisai and US biotech major Biogen have announced that the latest findings demonstrating the benefits of continuous ...

Lilly’s Kisunla and Biogen/Eisai’s Leqembi can both continue to slow Alzheimer's cognitive decline after more than three ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Biogen (NASDAQ:BIIB) traded ~8% higher in the premarket on Thursday after the company posted better-than-expected financials ...

Eisai and Biogen's Alzheimer's drug Leqembi continues to show promise in slowing disease progression, with no new safety issues observed over four years. The injectable form of Leqembi is under U.S.

A month away from the PDUFA decision date for a Leqembi (lecanemab) subcutaneous autoinjector to be used for maintenance ...

Eisai released 24-month data on Leqembi in November. Eisai presented the findings on Tuesday at the Alzheimer's Association International Conference in Philadelphia, the world's largest meeting ...

--BioArctic AB's partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion for their fiscal year 2025, corresponding to a 73 percent growth compared to the previous year.

STOCKHOLM, May 15, 2025 /PRNewswire/ -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that Leqembi sales are expected to total JPY 76.5 billion (approximately SEK ...